ROBERT MORTON: Open Payments
NPI 1336222504 · ADA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$520,657 in 833 payments from 16 companies in 2025. Trend: 2023 $302,666 · 2024 $412,414 · 2025 $520,657
Speaker / faculty: $420,238Consulting: $50,486Travel & lodging: $36,018Food & beverage: $13,680Education: $235
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 235 | $133,260 |
| Teva Pharmaceuticals USA, Inc. | 112 | $116,554 |
| Neurocrine BioSciences, Inc. | 151 | $96,023 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 99 | $76,378 |
| Janssen Pharmaceuticals, Inc | 52 | $33,291 |
| Alkermes, Inc. | 45 | $26,473 |
| Otsuka America Pharmaceutical, Inc. | 35 | $16,387 |
| ABBVIE INC. | 29 | $12,217 |
| Vanda Pharmaceuticals Inc. | 40 | $9,377 |
| Supernus Pharmaceuticals, Inc. | 10 | $178 |
Products named: COBENFY, INGREZZA, CAPLYTA, UZEDY, AUSTEDO XR, INVEGA SUSTENNA, LYBALVI, REXULTI.
Industry payments across OK — which companies pay providers there.
